CLDN18

Across TCGA pan-cancer cohorts, CLDN18 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of CLDN18’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where CLDN18 RNA is repressed in tumor relative to normal tissue. In most cancer types CLDN18 is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

LUAD, LUSC, and HNSC are the cancer types where CLDN18 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CLDN18 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	III,IV	−7.576	<.001	11	view →
LUSC	Female	II,III,IV	−8.277	<.001	9	view →
HNSC	Male	III,IV	+0.656	<.001	8	view →
KICH	Female	II,III,IV	−0.548	<.001	8	view →
BRCA	All	III,IV	−0.298	<.001	6	view →
UCEC	All	All	−0.170	<.001	6	view →
LIHC	All	All	+0.090	<.001	6	view →
THCA	All	All	−0.093	<.001	5	view →
PAAD	Female	All	+5.515	.030	4	view →
COAD	All	All	+0.789	.005	4	view →
CHOL	Female	All	+0.683	.004	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

CLDN18–LUAD

Open the LUAD breakdown →